Strategic partnerships OnDosis is actively pursuing collaborations with biotech and pharma players to advance drug-device combination products and personalized dosing solutions, signaling potential co-development or licensing opportunities for sales teams.

Clinical expansion The company is targeting unmet needs across ADHD, food allergies, pain management, and immunosuppression for transplants, presenting multiple verticals where you can position dosing technology as a differentiator in early to late-stage opportunities.

Digital health edge With a focus on dose customization delivered through the Dosage Manager and integrations like Camallergy, OnDosis emphasizes digital product capabilities and accessibility, suggesting upsell avenues to partners seeking patient-centric dosing platforms.

Early-stage traction Founded as a spin-out from AstraZeneca and backed by 11M in funding, OnDosis shows growth momentum and credibility that can support introductions to strategic investors, pharma licensees, and potential co-development partners.

Global reach via branding Recent awards and international collaborations, along with a scalable OYSTA platform and a global-minded footprint, create talking points for exploring distribution deals, contract manufacturing partnerships, and regional market entry collaborations.